• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid-resistant vitiligo: A prospective case series.

作者信息

Zhu Yijian, Shi Zhengzhou, Xu Zhongyi, Liu Suqing, Zhang Jian, Wang Qianqian, Liu Ye, Zhang Chengfeng, Jiang Min, Xiang Leihong

机构信息

Department of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, China.

出版信息

J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e128-e130. doi: 10.1111/jdv.20109. Epub 2024 Jun 10.

DOI:10.1111/jdv.20109
PMID:38853646
Abstract
摘要

相似文献

1
Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid-resistant vitiligo: A prospective case series.口服托法替布、巴瑞替尼和乌帕替尼单药治疗激素抵抗型白癜风：一项前瞻性病例系列研究。
J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e128-e130. doi: 10.1111/jdv.20109. Epub 2024 Jun 10.
2
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.托法替布、巴瑞替尼、乌帕替尼、费卢替尼和培非替尼单药治疗活动性类风湿关节炎的疗效和安全性比较。
J Clin Pharm Ther. 2020 Aug;45(4):674-681. doi: 10.1111/jcpt.13142. Epub 2020 Jun 3.
3
Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.在初治的类风湿关节炎患者中，与甲氨蝶呤相比，托法替布、巴瑞替尼、乌帕替尼和菲诺替尼的缓解率和低疾病活动率相对较高。
Pharmacology. 2023;108(6):589-598. doi: 10.1159/000527186. Epub 2023 Aug 17.
4
Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.托法替布、巴瑞替尼和乌帕替尼治疗类风湿关节炎的疗效和安全性：系统评价和荟萃分析。
Mayo Clin Proc. 2020 Jul;95(7):1404-1419. doi: 10.1016/j.mayocp.2020.01.039. Epub 2020 Jun 1.
5
Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.三种获批用于治疗类风湿关节炎的 Janus 激酶抑制剂（托法替布、巴瑞替尼和乌帕替尼）的药代动力学药物相互作用潜力的关键性评估。
Drug Saf. 2020 Aug;43(8):711-725. doi: 10.1007/s40264-020-00938-z.
6
Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.所有的 JAK 抑制剂在治疗类风湿关节炎方面都等效吗？托法替布、巴瑞替尼、乌帕替尼和费乐替尼疗效的调整间接比较。
Clin Rheumatol. 2023 Dec;42(12):3225-3235. doi: 10.1007/s10067-023-06787-2. Epub 2023 Oct 13.
7
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.比较托法替布、巴瑞替尼、乌帕替尼和菲卓替尼治疗生物制剂难治性活动性类风湿关节炎的疗效和安全性。
Z Rheumatol. 2021 May;80(4):379-392. doi: 10.1007/s00393-020-00796-1.
8
Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration.向美国食品药品监督管理局报告的Xeljanz/Xeljanz XR、Olumiant和Rinvoq不良事件的特征。
J Manag Care Spec Pharm. 2022 Sep;28(9):1046-1052. doi: 10.18553/jmcp.2022.28.9.1046.
9
One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.临床实践中类风湿关节炎患者的一年用药依从性和持续性：乌帕替尼、阿达木单抗、巴瑞替尼和托法替布的回顾性分析。
Adv Ther. 2023 Oct;40(10):4493-4503. doi: 10.1007/s12325-023-02619-6. Epub 2023 Aug 5.
10
Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.比较托法替布、巴瑞替尼、乌帕替尼和氟可替尼与甲氨蝶呤在类风湿关节炎初治患者中的疗效和安全性。
Z Rheumatol. 2021 Nov;80(9):889-898. doi: 10.1007/s00393-020-00889-x. Epub 2020 Sep 24.

引用本文的文献

1
A 5-week low-dose prednisolone regimen for progressive vitiligo: efficacy and safety in a single-center cohort study.一项针对进展期白癜风的为期5周的低剂量泼尼松龙治疗方案：单中心队列研究中的疗效与安全性
Ann Med. 2025 Dec;57(1):2543523. doi: 10.1080/07853890.2025.2543523. Epub 2025 Sep 1.
2
A case of vitiligo secondary to discoid lupus erythematosus treated with tofacitinib.1例盘状红斑狼疮继发白癜风患者接受托法替布治疗。
Medicine (Baltimore). 2025 Jun 27;104(26):e43118. doi: 10.1097/MD.0000000000043118.
3
Upadacitinib Monotherapy in Vitiligo Associated with Atopic Dermatitis: Killing Two Birds with One Stone.
乌帕替尼单药治疗与特应性皮炎相关的白癜风：一石二鸟。
Case Rep Dermatol. 2025 Feb 28;17(1):91-95. doi: 10.1159/000544703. eCollection 2025 Jan-Dec.
4
A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatment.口服托法替布治疗活动性白癜风的疗效和安全性回顾性分析。
Arch Dermatol Res. 2025 Mar 28;317(1):645. doi: 10.1007/s00403-025-04151-9.
5
Relative Impact of Monotherapies for Vitiligo: A Network Meta-Analysis Study.白癜风单一疗法的相对影响：一项网状Meta分析研究。
J Cosmet Dermatol. 2025 Mar;24(3):e70078. doi: 10.1111/jocd.70078.
6
Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study.巴瑞替尼与窄谱中波紫外线联合治疗活动性非节段型白癜风：一项回顾性对照研究。
Clin Cosmet Investig Dermatol. 2024 Dec 18;17:2933-2944. doi: 10.2147/CCID.S501688. eCollection 2024.